Small-scale Biomanufacturing Benefits from Disposable Bioreactors - Two-compartment bioreactors combine high cell density yields with an easy-to-use design for optimum biomanufacturing results - BioPh


Small-scale Biomanufacturing Benefits from Disposable Bioreactors
Two-compartment bioreactors combine high cell density yields with an easy-to-use design for optimum biomanufacturing results

BioPharm International
Volume 18, Issue 12

Table 1. Comparison of Different Disposable Cell Culture Systems for MAb Production (Modified after McArdle4)
Small-scale HFBs have been displaced by membrane-based two-compartment systems, which have proven to be more cost effective and simpler to use. Currently, two systems are available: the two-compartment roller bottle miniPERM (designed by the German-based In Vitro Systems & Services GmbH) and the static flask CELLine (INTEGRA Biosciences AG, Switzerland).1-4 As shown in Figure 1, the core element of the CELLine system is the cell compartment, which is formed by two different membranes incorporated into the bottom of the cell-culture flask. The upper membrane separates the cell compartment from the medium compartment and is made of a semi-permeable cellulose acetate sheet for exchange of metabolites between the two compartments. The lower membrane is made of gas-permeable silicone and guarantees efficient oxygen and CO2 transfer between the cell compartment and the incubator. Because the cell compartment is only 2 to 3 mm thick, efficient oxygenation is achieved by simple diffusion, hence avoiding the need for agitation and the resulting detrimental shear stress.

As illustrated in Figure 1, cells and the secreted expressed proteins accumulate in the cell compartment, located at the bottom of the flask, separated from the medium compartment by a dialysis membrane, indicated by a line of dashes (---) in the diagram. Nutrients smaller than 10 kDa freely diffuse through this dialysis membrane, thereby sustaining cell growth. Similarly, but in the opposite direction, toxic catabolites cross the dialysis membrane and are removed from the cells' surroundings. Efficient gas exchange takes place through the gas-permeable silicone bottom of the cell compartment membrane, indicated by a line of dots () in the diagram.


Figure 1. Schematic Representation of the Two-Compartment Set-up in a CELLine 1000 Bioreactor
Due to the high reaction specificity of MAbs, the production scale necessary for research and development applications, for in vitro diagnostics, or for quality control purposes does usually not exceed 1,000 mg. In the comparative analysis presented here and summarized in Table 2, we consider the costs arising during production of 200 mg MAbs using either a CELLine 1000 or conventional non-compartmentalized systems (roller bottles and a stirred bioreactor). Different production parameters need to be defined according to the required yield and to the culture system used (listed in the upper section of Table 2). The production process depends on productivity of the hybridoma clone used, i.e., on the amount of MAb produced per mL culture supernatant. In conventional cultivation systems, the maximal hybridoma density achieved is approximately 106 cells/mL, and typical productivity values found in the literature are 0.01 to 0.05 mg/mL.1-4 It must be noted that productivity can be considerably inferior when using a "low secretor" clone, as is often the case when productivity is not considered during clone selection. The other parameter influencing the production process is the volume of produced supernatant. Concerning the roller bottle and the stirred bioreactor, a supernatant volume of 300 mL and 5,000 mL per culture vessel has been defined, respectively. When assuming a productivity of 0.04 mg/mL and a batch culture protocol (i.e., one harvest per cultivation vessel), the volume of supernatant required to yield 200 mg MAb amounts to 5 L, which requires the use of 17 roller bottles or one bioreactor run.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here